Myeloma bone disease: from biology findings to treatment approaches

Bone disease is a cardinal complication of multiple myeloma that affects quality of life and survival. Osteocytes have emerged as key players in the development of myeloma-related bone disease. Along with other factors, they participate in increased osteoclast activity, decreased osteoblast function...

Full description

Saved in:

Bibliographic Details
Published in:	Blood Vol. 133; no. 14; p. 1534
Main Authors:	Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Dimopoulos, Meletios A
Format:	Journal Article
Language:	English
Published:	United States 04.04.2019
Subjects:	Bone Diseases - drug therapy Bone Diseases - etiology Denosumab - therapeutic use Humans Multiple Myeloma - complications Multiple Myeloma - drug therapy Osteocytes - pathology
ISSN:	1528-0020, 1528-0020
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Bone disease is a cardinal complication of multiple myeloma that affects quality of life and survival. Osteocytes have emerged as key players in the development of myeloma-related bone disease. Along with other factors, they participate in increased osteoclast activity, decreased osteoblast function, and immunosuppressed marrow microenvironment, which deregulate bone turnover and result in bone loss and skeletal-related events. Denosumab is a novel alternative to bisphosphonates against myeloma bone disease. Special considerations in this constantly evolving field are thoroughly discussed.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	1528-0020 1528-0020
DOI:	10.1182/blood-2018-11-852459